CRBU CARIBOU BIOSCIENCES INC

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:

  • 2025 Truist Securities BioPharma Symposium, New York

    November 6, 2025
  • 8th Annual Evercore Healthcare Conference, Coral Gables, FL

    December 2, 2025 with fireside chat at 8:45-9:05 AM ET





For more information and links to webcasts, please visit the page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies.

Caribou Biosciences, Inc. contact:

Peggy Vorwald, PhD





EN
03/11/2025

Underlying

CRBUCARIBOU BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CARIBOU BIOSCIENCES INC

 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Reports Third Quarter 2025 Financial Results and P...

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class allogeneic CAR-T cell therapy for LBCLCB-011 CaMMouflage phase 1 data demonstrate deep, durable responses and manageable safety, highlighting its potential as a best-in-class allogeneic CAR-T cell therapy for r/r multiple myeloma$159.2 million in cash, cash equivalents, and marketable securities as of...

November 12, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences to Participate in Upcoming Investor Conferences BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: 2025 Truist Securities BioPharma Symposium, New YorkNovember 6, 2025 8th Annual Evercore Healthcare Conference, Coral Gables, FLDecember 2, 2025 with fireside chat at 8:45-9:05 AM ET For more information and links to webcasts, please visit the page on Caribou’s website. W...

November 3, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial ...

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on patients who received optimized vispa-cel (N=35) 82% ORR, 64% CR rate, 51% PFS at 12 months in patients prospectively enrolled in partial HLA matching confirmatory cohort (...

November 3, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 T...

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma450 million cell dose is the recommended dose for expansion (RDE); dose expansion to initiate by year end and data expected in 202692% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve cohort treated at the RDE with the selected lymphodepletion regimenConference call and webcast scheduled for today at 8:00 am ET ...

November 3, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences to Host Webcast to Report New Data Updates from Tw...

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at 8:00 am ET on Monday, November 3, 2025, to report new data from the ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, in patients with...

November 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch